Glenmark Sets Sights On Regional Out-Licensing, Lot Riding On US Rhinitis NDA

 
• By Anju Ghangurde

With a basket of interesting R&D assets in hand, India’s Glenmark says it is pursuing regional out-licensing deals, including in Japan and China, for some of its molecules. Expectations are also running high on the firm’s first US NDA submission for seasonal allergic rhinitis.

Success ladder leading to cloud and many short ones. Business, goal, competition, unique, progress, challenge, hope and leadership concept. EPS 8 vector illustration, no transparency
GLENMARK IS KEEN TO MONETIZE SOME OF ITS KEY R&D ASSETS VIA LICENSING

More from Business

More from Scrip